Symbols

PLSE

Pulse Biosciences·NASDAQ

--(--)

PLSE fundamentals

PLSE Q4 2025 Earnings

Pulse Biosciences (PLSE) released its earnings on Feb 19, 2026: revenue was 264.00K (YoY --), beat estimates; EPS was -0.1829 (YoY -10.58%), beat estimates.

Revenue / YoY

264.00K

EPS / YoY

-0.1829

-10.58%

Report date

Feb 19, 2026

PLSE Earnings Call Summary for Q4,2025

Breakthrough Clinical Data: nPulse catheter achieves 96% 1-year success and 90% arrhythmia freedom, positioning for 2027 CE Mark. Surgical clamp IDE enrollment on track for 2026 completion.
Revenue Growth: Q4 2025 revenue up 207% QoQ to $264K, driven by Vybrance adoption in select accounts.
Strategic Focus: Disciplined commercialization, IP expansion, and $80.7M cash to fund 2026 clinical trials and partnerships.
Partnership Potential: Exploring mapping system integrations to accelerate electrophysiology adoption and procedure efficiency.

Earnings

EPS

Revenue

Revenue & Expenses

PLSE has released its 2025 Q4 earnings report, with revenue of 264.00K, reflecting a YoY change of NaN%, and net profit of -17.43M, showing a YoY change of 10.07%. The Sankey diagram below clearly presents PLSE's revenue sources and cost distribution.

Key Indicators

Pulse Biosciences (PLSE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pulse Biosciences (PLSE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pulse Biosciences (PLSE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pulse Biosciences (PLSE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown